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Short-term cftR inhibition reduces 
islet area in C57BL/6 mice
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James A. Shaw2, neville H. Mcclenaghan4, Viktória Venglovecz5, Attila Ébert5, 
Malin flodström-tullberg  3, Michael G. White2 & catriona Kelly1
Cystic fibrosis-related diabetes (CFRD) worsens CF lung disease leading to early mortality. Loss of 
beta cell area, even without overt diabetes or pancreatitis is consistently observed. We investigated 
whether short-term CFTR inhibition was sufficient to impact islet morphology and function in otherwise 
healthy mice. CFTR was inhibited in C57BL/6 mice via 8-day intraperitoneal injection of CFTRinh172. 
Animals had a 7-day washout period before measures of hormone concentration or islet function were 
performed. Short-term cftR inhibition increased blood glucose concentrations over the course of 
the study. However, glucose tolerance remained normal without insulin resistance. cftR inhibition 
caused marked reductions in islet size and in beta cell and non-beta cell area within the islet, which 
resulted from loss of islet cell size rather than islet cell number. Significant reductions in plasma insulin 
concentrations and pancreatic insulin content were also observed in cftR-inhibited animals. temporary 
CFTR inhibition had little long-term impact on glucose-stimulated, or GLP-1 potentiated insulin 
secretion. cftR inhibition has a rapid impact on islet area and insulin concentrations. However, islet 
cell number is maintained and insulin secretion is unaffected suggesting that early administration of 
therapies aimed at sustaining beta cell mass may be useful in slowing the onset of cfRD.
Cystic fibrosis (CF) is an autosomal recessive condition caused by mutations in the CF transmembrane conduct-
ance regulator (CFTR) gene, which encodes a cAMP activated chloride channel of the same name. CFTR is an 
apical membrane Cl−/HCO3− channel, which controls epithelial cell salt and fluid secretion across the plasma 
membrane. Abnormal CFTR leads to dehydrated, acidic secretions, which drive CF pathogenesis1. The vast 
majority of morbidity and mortality in CF results from lung disease where a build up of viscous mucous leads to 
bacterial colonisation of the airways and a decline in lung health. However, CFTR is highly expressed in various 
organs including the airways, pancreas and intestine2.
CF-related diabetes (CFRD) is the largest extra-pulmonary co-morbidity in the CF population and signifi-
cantly accelerates lung decline. In comparison to normoglycaemic individuals, patients with CFRD have worse 
pulmonary function, more frequent and severe pulmonary exacerbations, and a greater prevalence of bacteria in 
the sputum3. CFRD is present in 30–50% of adults with CF, and prevalence is rapidly increasing as CF life expec-
tancy improves4. The pathogenesis of CFRD remains poorly understood and extensive debate exists as to the role 
of CFTR in islet function and insulin secretion. Several investigators report CFTR channel activity in mouse5–8  
and human islets5,7 and show insulin and glucagon secretory defects in the absence of functional CFTR5–9. 
Conversely, others report that CFTR expression is very low or absent in human pancreatic endocrine cells10–12 
and suggest that impairments in insulin secretion likely result from decreased islet mass, intra-islet inflammation 
or exocrine-derived inflammatory mediators10,11.
Notwithstanding, the debate surrounding the location of CFTR within the pancreas, compelling evidence 
from human tissue and CF animal models consistently reports reductions in beta cell area and insulin content. 
Seminal studies in the pancreas of CF patients showed marked reductions in beta cell area irrespective of whether 
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diabetes was present or not13,14. This was confirmed in the CF ferret where altered islet morphology and function 
were reported at birth. In this model, a significant increase in the number of small islets was observed in neo-
nates15. Subsequent studies have repeatedly shown reductions in islet mass or beta cell area in animal models of 
CF16–19 and in post mortem pancreas from patients with CF10,20 including children under the age of 4 years20. In 
the latter study, beta cell area was reduced by as much as 50% in children less than 4 years old when compared 
with age-matched controls and this was shown to be independent of the degree of exocrine pancreatic fibrosis 
or the presence/absence of diabetes20. It is therefore clear that decreased islet and beta cell area occurs early in 
the pathogenesis of CF. In this study we wished to explore just how quickly this happened through the creation 
of a mouse model of short-term CFTR inhibition. To determine if any observed impact of CFTR was dependent 
on, or exacerbated by, hyperglycaemia, mice were exposed to CFTRinh172 alone or in combination with strep-
tozotocin. Streptozotocin-induced hyperglycaemia occurs via beta cell toxicity leading to a near absolute insulin 
requirement. The inhibition of CFTR in otherwise healthy animals allows for the assessment of whether CFTR 
has an essential role to play in the maintenance of islet area, whether loss of islet area could be attributed to devel-
opmental deficiencies, or whether loss of islet area is solely driven by a hyperinflammatory state in the pancreas.
Results
Short-term cftR inhibition impacts weight gain. Body weight change over the duration of the 
study is shown in Fig. 1a and the percentage change in body weight from Day -3 to Day 12 is shown in Fig. 1b. 
Control animals had significant weight gain over the course of the study (p < 0.05, Fig. 1a). Animals treated with 
CFTRinh172 alone showed a non-significant trend to weight gain (Fig. 1a). However, their percentage body 
weight gain from the start to the end of the study was significantly lower (60.3 ± 31.17% reduction; p < 0.01) 
than that of control animals (Fig. 1b). Streptozotocin treatment was associated with significant and comparable 
weight loss in the presence or absence of CFTRinh172 co-administration (Fig. 1a,b). Cumulative food and water 
intake were lower than in control animals during administration of STZ and CFTRinh172 alone or a combination 
(Fig. S2, ESM). Treatment of animals with STZ, CFTRinh172 or a combination of the two did not impact bone 
mineral content, bone mineral density or lean mass (Fig. S2, ESM). However, STZ treatment, alone or in combi-
nation with CFTRinh172 was associated with a reduction (p < 0.01) in fat mass (Fig. S2, ESM).
Figure 1. Body weight and blood glucose concentrations. Mice were treated with vehicle control, 
streptozotocin, CFTRinh172, or a combination of the two and (a) body weight over the duration of the study 
(Days -3, 1, 4, 7, 9 and 12), (b) percentage change in body weight from the beginning to the end of the study 
(Day -3 to Day 12), (c) blood glucose concentrations over the duration of the study (Days -3, 1, 4, 7 and 12), and 
(d) percentage change in blood glucose concentrations from the beginning to the end of the study (Day -3 to 
Day 12) were measured. Data are presented as mean ± SEM (n = 7–8 mice for all experiments). (a,c) *p < 0.05 
compared with values at Day -3 (t test). (b,d) **p < 0.01, ***p < 0.001 compared to control animals (One-way 
ANOVA).
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Short-term cftR inhibition does not induce hyperglycaemia or glucose intolerance. Control 
animals showed no change in blood glucose concentration over the course of the study. Animals treated with 
CFTRinh172 alone were not hyperglycaemic (Fig. 1c) but displayed a modest increase in blood glucose over the 
duration of the study (13.75 ± 7.28% increase between Day-3 and Day 12, p < 0.01, Fig. 1d). STZ treatment was 
associated with significant hyperglycaemia (Fig. 1c). STZ and CFTRinh172 co-administration led to a greater 
increase in glucose in comparison to STZ alone (Fig. 1d).
Glucose tolerance was tested over 90 minutes following i.p. administration of a glucose load on Day 12 of the 
study. Administration of CFTRinh172 alone had no significant impact on glucose tolerance (Fig. 2a,b). Multiple 
low dose streptozotocin alone, or in combination with CFTRinh172, was associated with fasting hyperglycaemia 
and abnormal glucose tolerance test (Fig. 2a,b). There were no significant differences between groups in fasting 
(Fig. 2c) or area under the curve serum (AUC) insulin (Fig. 2d). Consistently, calculation of HOMA-IR (Fig. S3a, 
ESM), HOMA-B (Fig. S3b, ESM), QUICKI (Fig. S3c, ESM) and measurement of phosphorylated IRS-1 in liver 
lysates (Fig. S3d), showed that animals treated with STZ, either alone or in combination with CFTRinh172, dis-
played evidence of insulin resistance and poor insulin sensitivity. Mice treated with CFTRinh172 alone were 
insulin sensitive (Fig. S3, ESM).
Short-term cftR inhibition reduces peripheral and pancreatic insulin concentrations. Plasma 
insulin, glucagon, and GLP-1 concentrations were assessed on the final day of the study following 2 hours fasting. 
In addition, the pancreatic content of each islet hormone was also investigated. Insulin concentrations (Fig. 3a,b) 
were reduced (p < 0.01) and glucagon concentrations (Fig. 3c,d) were elevated (p < 0.05) in STZ-treated animals. 
The current data show that short-term CFTR inhibition resulted in significant reductions in plasma insulin con-
centrations (36.40 ± 9.62% reduction, p < 0.01, Fig. 3a) and pancreatic insulin content (39.42 ± 9.74% reduction, 
p < 0.01, Fig. 3b). CFTR inhibition had little impact on glucagon or GLP-1 concentrations (Fig. 3).
Short-term cftR inhibition reduces islet cell size, not number. Sectioned pancreata were stained 
for insulin and glucagon (Fig. 4a). Islet area, beta cell area (insulin positive area) and non-beta cell area (total 
islet area minus insulin positive area) were calculated. Animals treated with STZ showed a reduction in islet size 
(p < 0.01, Fig. 4b), accompanied by a reduction in beta cell area (p < 0.001, Fig. 4c) and a significant increase in 
non-beta cell area (p < 0.001, Fig. 4d). Short-term CFTR inhibition caused significant reductions in islet area 
Figure 2. Glucose tolerance. Mice were treated with vehicle control, streptozotocin, CFTRinh172, or a 
combination of the two. Intraperitoneal glucose tolerance tests were undertaken on study Day 12 (a) Blood 
glucose concentrations and (c) plasma insulin concentrations were assessed immediately before and 15, 30, 
60 and 90 minutes after intraperitoneal administration of glucose (18 mmol/kg body weight). Respective 
areas under the curve for (b) blood glucose and (d) plasma insulin AUCs are also shown. Data are presented 
as mean ± SEM (n = 5–7 mice for all experiments). ***p < 0.001 compared to control animals (One-way 
ANOVA).
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(69 ± 20% reduction, p < 0.001, Fig. 4b), beta cell area (72 ± 20% reduction, P < 0.001, Fig. 4c) and non-beta 
cell area (56 ± 23% reduction, p < 0.001, Fig. 4d). To address whether the reductions in islet size resulted from 
changes in the number of islet cells or changes in the size of islet cells, insulin or glucagon positive cells were 
counted and expressed as a percentage of total islet cells (total DAPI counts per islet). As shown in Fig. 4e,f, 
the proportion of insulin and glucagon-positive cells per islet did not differ between control animals and those 
treated with CFTRinh172 alone. In contrast, the proportion of beta cells per islet decreased and the proportion 
of alpha cells increased in STZ-treated animals with and without CFTRinh172 co-administration. Finally, we 
assessed the percentage endocrine area (calculated as [endocrine area/exocrine area*100] where endocrine area 
comprised the cumulative area for all islets present in each section of tissue) for all animals (Fig. 4g). The mean 
endocrine area for control animals was 7.7 ± 0.8%. The percentage endocrine area of all other groups was signif-
icantly (p < 0.001) lower than that of control animals. The endocrine area of CFTRinh172-treated animals was 
3.4 ± 0.6% (Fig. 4g).
Short-term cftR inhibition does not alter beta-cell transcription factor expression. The pro-
portion of beta cells expressing the transcription factors Pdx-1 and Nkx6.1 was determined by expressing the 
number of cells co-stained for insulin and either Pdx-1 or Nkx6.1 as a percentage of total insulin positive cells. 
Multiple low-dose STZ, alone or in combination with CFTRinh172 significantly (p < 0.01 to p < 0.001) reduced 
the percentage of Pdx-1 (Fig. 5a,b) and Nkx6.1 (Fig. 6a,b) positive beta cells in C57BL/6 mice. No change in the 
percentage of Pdx-1 (Fig. 5a,b) or Nkx6.1 (Fig. 6a,b) positive beta cells was observed in animals treated with 
Figure 3. Islet hormone concentrations. Peripheral plasma concentrations of (a) insulin (n = 10–15), (c) 
glucagon (n = 6–8), and (e) GLP-1 (n = 5–8) were assessed on Day 12 of the study. Additionally, the pancreatic 
content of (b) insulin (n = 6–8), (d) glucagon (n = 7–8), and (f) GLP-1 (n = 5) were assessed in protein 
extracted from pancreatic tissue. All observations were made in mice fasted for 2 hours. Data are presented 
as mean ± SEM for a given number of mice (n) as indicated above. *p < 0.05, **p < 0.01 and ***p < 0.001 
compared to control animals (One-way ANOVA).
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CFTRinh172 alone. Consistently, the mRNA expression of PDX1 (Fig. 5c) or NKX6-1 (Fig. 6c) in isolated islets 
did not differ between control and CFTR-inhibited animals.
Insulin secretion is not influenced by short-term CFTR inhibition. Islets were isolated from mice 
treated with CFTRinh172 alone or vehicle control and challenged with glucose or the cAMP agonist GLP-1. In all 
instances, elevation of glucose concentration in the presence or absence of GLP-1 evoked significant increases in 
insulin release compared with the corresponding control under basal conditions (Fig. 7a). No significant differ-
ences were observed in glucose-stimulated insulin secretion or GLP-1 potentiated insulin secretion between vehi-
cle controls and animals treated with CFTRinh172 when absolute insulin concentrations were measured (Fig. 7a). 
Additionally, no significant differences were detected in the mRNA expression of several glucose sensing genes 
(SCLC2A2, GCK, ABCC8, KCNJ11) in islets from CFTR-inhibited mice (Fig. S4, ESM). However, when insulin 
Figure 4. Islet size and composition. (a) Representative images of pancreatic islets from mice treated with 
vehicle control, streptozotocin, CFTRinh172, or a combination of the two and stained for insulin (green), 
glucagon (red), and the nuclear stain DAPI (blue). (b) Islet area (µm2), (c) beta cell area [insulin positive area] 
(µm2), (d) non-beta cell area [non-insulin positive area] (µm2), (e) beta cell number as a percentage of total islet 
cells [insulin positive cells/DAPI count] and (f) alpha cell number as a percentage of total islet cells [glucagon 
positive cells/DAPI count]. Data are presented as mean ± SEM (n = 5 mice) and calculated from two sections 
of tissue per animal taken at least 200 µm apart. A minimum of 100 islets were counted from a total of 5 animals 
(at least 20 islets per animal). Each data point on the graphs represents one islet. **p < 0.01 and ***p < 0.001 
compared to controls animals (One-way ANOVA).
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Figure 5. Pdx-1 expression. (a) Representative images of pancreatic islets from mice treated with vehicle 
control, streptozotocin, CFTRinh172, or a combination of the two and stained for insulin (green), Pdx-1 (red), 
and the nuclear stain DAPI (blue). (b) Number of Pdx-1 positive cells as a percentage of beta cells (insulin 
positive cells). Data are presented as mean ± SEM (n = 5 mice). A minimum of 50 islets were counted from a 
total of 5 animals (at least 10 islets per animal). Each data point on the graphs represents one islet. ***p < 0.001 
compared to control animals (One-way ANOVA). (c) Relative PDX1 mRNA expression in the isolated islets of 
control animals and those treated with CFTRinh172 alone. Data are presented as mean ± SEM (n = 8).
Figure 6. Nkx6.1 expression. (a) Representative images of pancreatic islets from mice treated with vehicle 
control, streptozotocin, CFTRinh172, or a combination of the two and stained for insulin (green), glucagon 
(red), Nkx6.1 (grey), and the nuclear stain DAPI (blue). (b) Number of Nkx6.1 positive cells as a percentage of 
beta cells (insulin positive cells). Data are presented as mean ± SEM (n = 5 mice). A minimum of 50 islets were 
counted from a total of 5 animals (at least 10 islets per animal). Each data point on the graphs represents one 
islet. ***p < 0.001 compared to control animals (One-way ANOVA). (c) Relative NKX6-1 mRNA expression in 
the isolated islets of control and CFTR-inhibited mice. Data are presented as mean ± SEM (n = 8).
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secretion was adjusted for pancreatic insulin content, the fraction of insulin released from islets isolated from 
CFTRinh172-treated mice was significantly higher (p < 0.001) than that of vehicle controls under basal (1.1 mM) 
glucose concentrations (Fig. 7b).
Short-term cftR inhibition generates pancreatic and intestinal phenotypes that are consistent 
with cf disease. H&E staining of the pancreas revealed a significant (p < 0.001) reduction in islet size 
(Fig. 8a,b) and an increase (p < 0.01) in ductal area (Fig. 8a,c) in CFTR-inhibited animals consistent with obser-
vations from ΔF508 and CFTR KO mice (Fig. 8). Pancreatic inflammation is consistently reported in CF disease 
and recent work has shown that IL-6 plays a key role in islet dysfunction in CF ferrets11. In the current study, 
short-term CFTR inhibition did not cause an increase in IL-6 concentrations in the pancreas (Fig. S5, ESM) and 
there was little histological evidence of inflammatory cell infiltrate (See Fig. S7, ESM). Finally, intestinal villus 
height was not influenced by short-term CFTR inhibition, consistent with the ΔF508 model (Fig. S8, ESM).
Sirius red/fast green staining was undertaken to determine if there was any evidence of early stage fibrosis in 
the tissues of animals treated with CFTRinh172. Despite occasional evidence of additional collagen deposition 
around the pancreatic ducts and within the basement membrane of the intestine, the overall % area stained for 
Sirius red did not differ between control and CFTR-inhibited animals (Fig. S9, ESM).
Discussion
In the present study we generated a mouse model of short-term (8 day) CFTR inhibition using low-dose treat-
ment with the pharmacological CFTR inhibitor, CFTRinh172, in otherwise healthy mice. CFTRinh172 is a small 
molecule containing 2-thioxo-4-thiazolidinone core that acts to inhibit CFTR Cl− channel function by binding 
to the first nucleotide-binding domain of CFTR and stabilising closed channel state21,22. Following short-term 
administration of this inhibitor, we observed marked and consistent reductions in islet size that were associated 
with reduced pancreatic insulin content and reduced circulating insulin concentrations. Our data show that loss 
of CFTR function, even on a short-term basis is sufficient to mediate reductions in islet size and insulin content.
Previous studies have suggested that beta cell dysfunction and insulin deficiency results in impaired glucose 
tolerance in the majority of CF patients23. Glucose abnormalities are frequently observed in children with CF 
and in very rare cases, have been reported in infants under the age of 224–27. In the current study, CFTR-inhibited 
animals displayed a modest increase in blood glucose concentrations but were not diabetic. The animals also had 
normal glucose tolerance in response to an intraperitoneal glucose challenge. None of the observed effects of 
CFTR inhibition were dependent on, or exacerbated by, hyperglycaemia.
Islet area was reduced by some 70% in the present study, with beta cell and non-beta cell areas similarly 
reduced. Recently, Rotti et al.18 detailed changes in islet composition in CF ferrets of increasing age and phases 
of glycaemic regulation. In the ferret model, newborn animals and those up to the age of 4 months, displayed 
relatively similar distribution of insulin, glucagon and somatostatin positive cells. When the number of insulin, 
or glucagon-positive cells were counted as a percentage of total islet cells in this model of short-term CFTR inhi-
bition, it was evident that the reduction in islet size resulted from smaller islet cells rather than loss of cells. This is 
consistent with recent observations in the ΔF508 mouse19 and raises the attractive possibility that early interven-
tions to prevent reductions in islet mass may assist in the maintenance of normal islet size and function in CF. In 
line with the reductions in islet size, insulin content and peripheral insulin concentrations were also significantly 
reduced. Glucagon and GLP-1 concentrations were spared in this model.
Reductions in insulin secretion in the face of glucose challenge have been reported in several CF ani-
mal15,16,19,28 and cell models5–9, and in patients with CF28–33. Fontes et al.17 report that impairments in insulin 
secretion from the isolated islets of ΔF508 mice result from reductions in insulin content associated with loss of 
beta cell mass. Short-term CFTR inhibition had little impact on glucose-stimulated, or GLP-1 potentiated, insulin 
secretion in the current study even in the absence of any adjustment for insulin content. However, it should be 
Figure 7. Glucose stimulated insulin secretion. Islets were isolated from animals treated with vehicle control 
or CFTRinh172 and exposed to 1.1 mM glucose, or 16.7 mM glucose ± 10 nM GLP-1 for 1 h. (a) Static insulin 
release was measured by ELISA with *p < 0.05, **p < 0.01 and ***p < 0.001 compared to either 1.1 mM or 
16.7 mM glucose as indicated in the Figure (one-way ANOVA). (b) Data was adjusted for pancreatic insulin 
content under basal (1.1 mM) glucose conditions with ***p < 0.001 compared to corresponding control 
animals (t test). Data are presented as mean ± SEM (n = 8–10 for all experiments).
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noted that the inhibitor used here is reversible and therefore the washout period of 7 days may mean that an acute 
secretory defect was missed. However, it is noteworthy that the reductions in islet size and insulin content did 
not impact insulin secretion in response to challenge. Importantly, the fraction of insulin secreted under basal 
conditions was higher in CFTR-inhibited mice than vehicle controls, consistent with recent observations in the 
CF ferret11. This may explain the ability of these islets to function well in the face of GLP-1 challenge despite sig-
nificant reductions in size and insulin content.
Prior use of CFTRinh172 in vivo caused defects in the nasal epithelial ion transport in mice34, and reduced 
efficacy in submucosal gland fluid secretion in pig and human airways35. Nonetheless, we were conscious of the 
use of a pharmacological inhibitor of CFTR, which has the potential to generate off-target effects11,36,37. We have 
taken several steps to minimise this risk including low-dose use of the inhibitor, which has been reported to limit 
the potential for aberrant effects36. The literature suggests that mice will tolerate up to 50 mg/kg per day for 1 
week, or 3 mg/kg CFTRinh172 twice daily for a period of 6 weeks with little evidence of toxicity38. In the current 
study, we used the lower dose and administered the treatment once daily. Animals were also allowed a wash-out 
period of one week before most of the data presented here (including islet hormone concentrations, insulin secre-
tion and morphological analyses) were assessed. Although CFTR-inhibited animals weighed a little less than the 
control group, they otherwise appeared to tolerate the treatment well.
To further validate our model of short-term CFTR inhibition, we sought to characterise the phenotype created 
following CFTR inhibition and to compare this directly with a transgenic CF mouse model (ΔF508)39, a CFTR 
KO model40 and the known literature on CF disease. The pancreatic and intestinal phenotypes of CFTR-inhibited 
mice were largely consistent with CF disease. Islet size was reduced in CFTR-inhibited animals, and the ΔF508 
and CFTR KO animals, consistent with the literature17,19. In addition, ductal dilatation, a hallmark of CF dis-
ease, was evident in all three mouse models studied here. Intestinal villi height is occasionally reduced in CF41. 
However, in both the CFTR-inhibited model and the ΔF508 model, we observed no change in villi height.
Recent work suggested that pancreatic IL-6 concentrations contribute to islet dysfunction in CF ferrets11. 
However, IL-6 concentrations were not elevated in our model of CFTR inhibition and there was little histological 
evidence of inflammatory cell infiltrate within the islets. The absence of inflammation in this model does not 
negate the role of pancreatitis and intra-islet inflammation in the pathogenesis of CFRD. Indeed, it seems implau-
sible that the pancreatic environment in advanced CF disease would not impact islet function. However, these 
Figure 8. Pancreatic morphology. Representative H&E stained sections of the (a) pancreas of CFTRinh172-
treated mice and vehicle controls (both n = 5), transgenic ΔF508 mice and wild-type controls (both n = 3), 
CFTR KO mice (n = 3) and wild-type controls (n = 2). Islets are denoted by dashed white circles with pancreatic 
ducts identified by dashed rectangles. (b) Islet area and (c) pancreatic ductal area have been quantified. 
Values represent mean ± SEM calculated from two sections of tissue per animal taken at least 200 µm apart. 
A minimum of 20 data points (at least 10 per section) were collected for each animal. Each data point on 
the graphs represents one islet/duct. **p < 0.01 and ***p < 0.001 compared to corresponding control/wild 
type animals (t test). Please note that the representative image of the pancreas shown for the ΔF508 mice is a 
composite. The complete image is presented in Fig. S6, ESM.
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findings show that islets are impacted early after loss of CFTR, and suggest that these changes, even in the absence 
of overt inflammation/proinflammatory cytokine signalling, may contribute to islet dysfunction.
Here we report that short-term CFTR inhibition does not cause clinically significant glucose abnormalities, 
nor is it associated with spontaneous development of diabetes, a long-term defect in the secretory capacity of 
islets, pancreatic inflammation or fibrosis. This is in contrast with much of the published literature discussed 
above. It is likely that the acute duration of CFTR inhibition examined in this study was insufficient to trig-
ger several defects often associated with age. For example, Fontes et al.17 report glucose intolerance in 24-week 
old ΔF508 mice, but not in 12-week old animals. Moreover, we found little evidence of pancreatic inflamma-
tion in CFTR-inhibited animals as has been reported in transgenic animals11 and in adult CF patients10,20 where 
chronic disease has persisted for periods far beyond the acute 8-day duration of CFTR inhibition examined here. 
Consistently, pancreatic inflammation is less commonly observed in CF children20. Furthermore, the washout 
period following CFTR inhibition and the reversible nature of the inhibitor itself may mean that an acute func-
tional secretory defect has been missed.
In conclusion, the present observations provide further evidence that CFTR is essential to the maintenance 
of islet size and insulin content within the pancreas. The current model of global CFTR inhibition does not allow 
for distinction between islet intrinsic versus extrinsic roles of CFTR. However, the data shows that inhibition of 
CFTR has a rapid impact on islet size. Importantly, the use of healthy adult mice in this study excludes the possi-
bility that early loss of islet mass in the absence of functional CFTR is purely a developmental issue. The absence 
of inflammation in our model raises the possibility that additional trophic factors beyond the pancreas may be 
regulating islet mass in this state. The observations that (1) islet cell number is maintained even in the face of a 
reduction in area and that (2) the secretory capacity of islets is sustained despite significant reductions in insulin 
content, suggest that early administration of therapies aimed at sustaining beta cell mass may be useful in slowing 
the onset of CFRD.
Methods
Animal models. Animal studies were conducted in male C57BL/6 mice exposed to a pharmacological 
inhibitor of CFTR, CFTRinh172. Experiments were licensed according to UK Home Office regulations (UK 
Animals Scientific Procedures Act 1986) and associated guidelines (EU Directive 2010/63/EU) and approved by 
the University of Ulster Animal Ethics Review Committee. The pancreatic (and where possible, intestinal) phe-
notypes of CFTR-inhibited mice were compared with those of Cftrtm1EUR mice39, hereafter referred to as ΔF508 
mice, and CFTR KO mice40. Further information on the age, genetic background, and the husbandry and mainte-
nance of the mice is provided in the methods section of the electronic supplementary material (ESM).
In vivo studies. C57BL/6 mice were age-matched and grouped based on their fasted blood glucose and body 
weight. The dosing regimen is described in Fig. S1 (ESM). In brief, animals received once daily intraperitoneal 
(i.p.) injections of vehicle control (DMSO) or CFTRinh172 (3 mg/kg body weight) for 8 consecutive days starting 
on Day -3. To determine if the effects of CFTR inhibition were dependent on, or exacerbated by, hyperglycae-
mia, CFTRinh172 was administered alone or in combination with a low dose streptozotocin (STZ; 50 mg/kg 
body weight) regimen, which began on Day 0 of the study and continued for 5 consecutive days. This resulted 
in the creation of 4 groups of animals: (1) vehicle control; (2) STZ-treated; (3) CFTRinh172-treated; and (4) 
STZ + CFTRinh172-treated. Specific information on the routine measurement of body mass composition, blood 
glucose and glucose tolerance tests are given in Fig. S1 and in the methods section of the ESM.
After a 7-day washout period, mice were killed by Schedule 1 methods and pancreata, intestines and terminal 
blood samples collected. Pancreata were halved longitudinally from head to tail with one half used for histology 
and the other half used for islet isolation or determination of islet hormone content as described below and in 
the ESM.
Determination of islet hormone concentrations. Commercially available ELISAs were used to meas-
ure insulin (Ultra-sensitive murine insulin ELISA, Mercodia), glucagon (Glucagon Quantikine ELISA Kit, R&D 
Systems) and GLP-1 (GLP-1 EIA Kit, Sigma-Aldrich) concentrations according to the manufacturers’ instruc-
tions. Further details on the processing of plasma and pancreatic protein extract for assessment of islet hormone 
concentrations is given in the methods section of the ESM.
islet isolation and determination of insulin secretion. Islets were isolated from vehicle control 
and CFTR-inhibited mice by collagenase digestion, as previously described42. Islets were cultured overnight in 
RMPI supplemented with 10% FBS and 1% Penicillin/Streptomycin at 37 °C and 5% CO2 prior to experimenta-
tion. Batches of ten islets underwent static incubation in basal glucose (1.1 mM D-glucose) for 1 hour, followed 
by exposure to test solution (1.1 mM D-glucose, or 16.7 mm D-glucose ± 10 nM GLP-1) for a further 1 hour. 
Supernatants were collected and the secretion of insulin assessed by ELISA (Ultra-sensitive murine insulin 
ELISA, Mercodia).
expression of islet regulatory genes. The mRNA expression of islet regulatory genes was assessed 
by qPCR. mRNA was extracted from isolated mouse islets42 using a RNeasy Mini Kit following manufactur-
er’s instructions (Qiagen, UK). mRNA (200 ng) was reverse transcribed to cDNA using transcriptor first strand 
cDNA synthesis kit (Roche, Burgess Hill, UK). UK). qPCR was performed on a Lightcycler 480 System (Roche, 
UK) using custom designed probes (Roche). Probe IDs are provided in Table S1 (ESM) and further information 
on cycling conditions and quantification of relative expression are available in the methods section of the ESM.
Immunofluorescent staining of pancreatic tissue. Pancreatic tissues were immediately fixed, pro-
cessed and embedded in paraffin wax using an automated tissue processor (Leica TP1020, Leica Microsystems, 
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Nussloch, Germany), as described previously43. Tissues were stained with appropriate primary (Table S2, ESM) 
and secondary antibodies (Table S3, ESM). Full details on tissue processing and staining are given in the ESM. 
Slides were mounted with anti-fade mounting medium (Vectashield, Vector Laboratories) with DAPI and viewed 
using a Nikon A1 confocal microscope (Nikon UK Limited, Surry, United Kingdom). All staining procedures and 
image analysis were carried out in a blinded manner.
phenotypic characterisation of pancreatic and intestinal tissue. Pancreata and intestines from mice 
treated with CFTRinh172, ΔF508, and CFTR KO mice and corresponding control animals were fixed, processed 
and sectioned as described. Haematoxylin and Eosin staining (H&E) was conducted as previously described44. 
Quantification of collagen deposition was conducted using the sirius red/fast green method. Briefly, 4 μm sections 
were deparaffinised, rehydrated and incubated in 0.1% Fast Green for 5 minutes. Following rinsing in distilled 
water, sections were incubated in 0.5% Sirius Red for 10 minutes before counterstaining with Haematoxylin, 
rinsed in Scott’s Tap Water and mounted with Pertex (CellPath).
image analysis. For measurements of islet size, beta cell area, non-beta cell area and endocrine:exocrine 
area, two sections of tissue separated by at least 200 µm were analysed for each animal. Measurements from a 
minimum of 20 data points (i.e. at least 10 islets per section) were collected per animal from at least 5 different 
mice. Nikon NIS-AR image analysis software (NIS Elements) was used to analyse islet parameters including islet 
area, alpha cell area (glucagon positive area) and beta cell area (insulin positive area), expressed as µm2. Islet 
parameters were determined using the ‘closed polygon’ tool in analysis software. The number of cells per islet 
were manually counted using cell counter in ImageJ software. For assessment of the percentage Pdx-1 and Nkx6.1 
positive cells within the islet, analyses were performed on at least 10 islets per animal from five different mice and 
further validated by qPCR.
Statistical analysis. Statistical analysis was performed using GraphPad PRISM (La Jolla, CA, USA; ver-
sion 7). Data are presented as mean ± SEM for a given number of observations (n) as indicated in the Figures. 
All samples were numbered and blinded, and researchers were unblinded only when analyses were complete. 
Differences between groups were compared using one-way ANOVA or unpaired 2-tailed Student’s t test as appro-
priate. Statistical significance was accepted at p < 0.05.
Data Availability
The datasets generated during and/or analysed during the current study are available from the corresponding 
author on reasonable request.
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